Regulatory Bayer wins MHRA approval for Kerendia in heart failure PharmaTimesNew authorisation offers additional option for patients with lvef 40%RegulatoryCardiovascularRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) PharmaTimes New authorisation offers additional option for patients with lvef 40% RegulatoryCardiovascularRead full story Post navigation Previous: Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumorsNext: FDA hands another rejection to Replimune’s melanoma therapy Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
